Full text loading...
Therapeutic Research
Abstract
Objectives:High‒dose of metformin was approved in 2010 and fixed dose combination of metformin and DPP‒4 inhibitor(DPP4i)was launched in 2016, thus diversifying the usage of metformin. In this report, the actual usage status of metformin and DPP‒4i was investigated in patients with type 2 diabetes. Methods:Using prescription data from the Japan Medical Data Center, patients were classified into three groups which were comprised all patients who were prescribed metformin(whole group), patients prescribed metformin alone(Met‒alone group)and patients prescribed a combination of metformin and DPP‒4i (combination group). The actual status of metformin and DDP‒4i prescription was analyzed in these groups. Results:The proportion of young patients tended to be higher in Met‒alone group than in the whole group and the combination group. DPP‒4i was co‒administered with metformin in 66‒67% of patients in all groups. The mean daily dosage of metformin in the Met‒alone group(792.8 mg) was relatively low compared with that in the whole group(916.4 mg)and the combination group(928.9 mg). Metformin was administered twice daily at 250 or 500 mg/day in most patients in all groups. Conclusions:In this observation, it was indicated that metformin was administered at 500 or 750<‒1000 mg/day in most patients. It was also shown that combined medication with metformin and DPP‒4i was the leading therapy for oral medication in patients with type 2 diabetes. Additional studies are needed to clarify the usage status of metformin and DPP4i by patient background such as comorbidity and body mass index.
Data & Media loading...